Voyager Therapeutics (VYGR) Receivables - Net (2022 - 2026)

Voyager Therapeutics has disclosed Receivables - Net across 5 years of filings, most recently posting $1.5 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $1.5 million, down 7.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 7.95% YoY), and the FY2025 annual result was $1.8 million, up 17.09% from the prior year.
• Receivables - Net came in at $1.5 million for Q1 2026 at Voyager Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $80.1 million in Q4 2023 to a low of $837000.0 in Q1 2024.
• The 5-year median for Receivables - Net is $1.7 million (2024), against an average of $12.1 million.
• Across the five-year window, Receivables - Net slumped 98.12% in 2024 and soared 93.91% in 2025, its largest moves.
• Voyager Therapeutics' Receivables - Net stood at $10.0 million in 2022, then soared by 701.5% to $80.1 million in 2023, then plunged by 98.12% to $1.5 million in 2024, then gained by 17.09% to $1.8 million in 2025, then retreated by 15.16% to $1.5 million in 2026.
• The last three Receivables - Net figures came in at $1.5 million (Q1 2026), $1.8 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.